NCT01532973View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 16, 2012

Primary Completion Date

May 17, 2013

Study Completion Date

May 17, 2013

Conditions
Hepatitis, Viral, Human
Interventions
DRUG

Elbasvir

Elbasvir was administered orally by tablet(s)

DRUG

Placebo

Dose-matched placebo tablets were administered orally.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01532973 - Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002) | Biotech Hunter | Biotech Hunter